BRAF and metastatic melanoma: In 2011 the first BRAF inhibitor was approved for metastatic melanoma patients with BRAF V600E/K mutated tumors, which would be followed by combination BRAF and MEK inhibition therapy (Chapman et al., 2011; Flaherty et al., 2012).